News
The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...
3d
MedPage Today on MSNFirst-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast CancerCHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...
The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.
US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
1don MSN
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...
3don MSN
Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...
The accused individuals were selling spurious cancer medicines and injections, including Opdivo, Pembrolizumab Injection, Keytruda, and others, without proper authorisation. The police raided three ...
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results